Macular Hole Formation After Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration
Chandoshi Mukherjee*, Arijit Mitra, N. Ajith Kumar, Samer Elsherbiny, Peck Lin Lip
Identifiers and Pagination:Year: 2015
First Page: 177
Last Page: 180
Publisher ID: TOOPHTJ-9-177
Article History:Received Date: 30/7/2015
Revision Received Date: 7/9/2015
Acceptance Date: 7/9/2015
Electronic publication date: 31/12/2015
Collection year: 2015
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Ranibizumab is a monoclonal antibody fragment that inhibits angiogenesis by inhibiting vascular endothelial growth factor A, used as a treatment for patients with wet aged-related macular degeneration (ARMD). Adverse effects from intravitreal Ranibizumab injections are well recognised. Macular hole formation following Ranibizumab injection is a complication that has been recently reported in few case reports. We present a larger case series of five patients, who developed full thickness macular holes (FTMH) after intravitreal Ranibizumab injections for treatment of wet ARMD that we were aware of between 2009 and 2013.